Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734908 | 1.00 | KCNH2 (0.46) | KCNH2DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL736431 | 1.00 | KCNH2 (0.46) | KCNH2DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL757229 | 1.00 | KCNH2 (0.46) | KCNH2DRD2DRD3SIGMAR1HTR2C | |
| SCHEMBL736826 | 0.87 | DRD2 (0.41) | KCNH2DRD2DRD3HTR2CHTR2A | |
| SCHEMBL1555849 | 0.82 | ADAMTS5 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1556226 | 0.82 | ADAMTS5 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL736169 | 0.81 | ADAMTS5 (0.36) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL737169 | 0.81 | ADAMTS5 (0.36) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL733841 | 0.81 | ADAMTS5 (0.36) | KCNH2DRD2DRD3SLC6A2SLC6A4 | |
| SCHEMBL733840 | 0.81 | ADAMTS5 (0.36) | KCNH2DRD2DRD3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | KCNH2 2018/4885DRD2 349/4885DRD3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.